为您找到相关结果约500个

你是不是要搜索 期刊Durvalumab+plus+610+monalizumab,+mFOLFOX6,+and+bevacizumab+in+patients+(pts)+with+metastatic+microsatellite-+611+stable+colorectal+cancer+(MSS-CRC).+ 点击跳转

Durvalumab plus monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stablecolorectal cancer (MSS-CRC)

First-line durvalumab plus monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stablecolorectal cancer (MSS-CRC)

First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastaticmicrosatellite-stable colorectal cancer.

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with PreviouslyUntreated Metastatic Colorectal Carcinoma (mCRC)

Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastaticcolorectal cancer (mCRC).

Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastaticcolorectal cancer (mCRC)

Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastaticcolorectal cancer (mCRC): Interim analysis.

Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients withadvanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLACRC cohort results

Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellitestable (MSS) colorectal cancer (CRC) patients (pts).

Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T)following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable(MSS) metastatic colorectal cancer (mCRC) progress

Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients(pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

Microsatellite-Stable Colorectal Cancer (MSS CRC) Shows Enrichment for Loss of Neoantigenic Mutations(NAMs) Compared to CRC with Microsatellite Instability (MSI)

NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab(T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable(MSS) metastatic colorectal cancer (mCRC)

A phase II study of durvalumab (MEDI4736) (anti-PDL1) and trametinib (MEKi) in microsatellite stable(MSS) metastatic colorectal cancer (mCRC)

Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectalcancer

为您找到相关结果约500个

共500条页码: 1/34页15条/页